Making the compound Amanitin available for cancer therapies

Our focus is on oncology and our mission is to research and develop drugs for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

ADC Drug Development

As a drug development company we concentrate on combining the targeting properties of antibodies with the effectiveness of an ultra-potent toxin with antibody-drug conjugates (ADC), that are more effective against cancer. 

Key USP of our technology is the potential to treat multi-resistant tumors and "dormant or quiescent" tumor cells, which are regarded as a main reason for metastasis and resistance.

Read more

Latest Releases

Latest News

  • 11.10.2018
    Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate
  • 11.10.2018
    Heidelberg Pharma AG: Interim management statement on the first nine months of 2018
  • 23.08.2018
    Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
  • 12.07.2018
    Heidelberg Pharma reports on first half-year
  • More Press Releases
By Master en comunicación

Services

As a preclinical CRO we offer explorative pharmacology, drug metabolism and pharmacokinetics (DMPK) analysis and molecular biology.

Our core competence is the preclinical profiling of small molecules or biologicals destined for the treatment of cancer or inflammatory/autoimmune diseases.

Read More

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.